Table 4.

Ruxolitinib dose modifications recommended for myelofibrosis patients with starting platelet count of at least 100 × 10⁹/l^*

	Dose at time of decline in platelet count					Maximum dose based on platelet count after prior treatment interruption or dose reduction
	25 mg b.i.d.	20 mg b.i.d.	15 mg b.i.d.	10 mg b.i.d.	5 mg b.i.d.
Current platelet count	New dose to be used
≥125 × 109/l	No change	No change	No change	No change	No change	20 mg b.i.d.
100 to <125 × 109/l	20 mg b.i.d.	15 mg b.i.d.	No change	No change	No change	15 mg b.i.d.
75 to <100 × 109/l	10 mg b.i.d.	10 mg b.i.d.	10 mg b.i.d..	No change	No change	10 mg b.i.d. for 2 weeks; if stable, may increase to 15 mg b.i.d.
50 to <75 × 109/l	5 mg b.i.d.	5 mg b.i.d.	5 mg b.i.d.	5 mg b.i.d.	No change	5 mg b.i.d. for 2 weeks; if stable, may increase to 10 mg b.i.d.
<50 × 109/l	Hold	Hold	Hold	Hold	Hold	Continue holding

For insufficient response, closes may be increased in 5-mg b.i.d. increments to a maximum of 25 mg b.i.d., provided that platelet and neutrophil counts are adequate.

See full prescribing information for a complete description of US FDA-approved dosing of ruxolitinib in patients with intermediate or high-risk myelofibrosis.

^*Starting ruxolitinib doses of 15 mg b.i.d. for patients with platelet counts of 100–200 × 10⁹/l and 20 mg b.i.d. for those with a platelet count greater than 200 × 10⁹/l.

Recommended dose modifications based on US prescribing information.

b.i.d.: Twice daily.

Data taken from [32].